Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genomics England

- PMLiVE

Election 2019: Labour tops Tory pledge on NHS spending

Pledge comes as campaigning for upcoming election gathers steam

- PMLiVE

NICE backs first cannabis-based drugs, both from GW Pharma

Approved to treat patients with epilepsy and multiple sclerosis

Understanding the evolving CAR-T market

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Blue Latitude Health

- PMLiVE

NHS leader warns politicians not to ‘weaponise’ the health service

Top exec challenges main parties to provide credible solutions to big issues

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

- PMLiVE

Pfizer raises forecast following growth of biopharma business

On the flip-side company reported decline in Upjohn generics division

- PMLiVE

UK government raises concerns about Illumina’s $1.2bn takeover of PacBio

CMA concludes the merger will result in loss of market competition

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

AstraZeneca AZ

AZ reports growth again in Q3, driven by oncology and China sales

Company has also returned to growth in Europe

AstraZeneca AZ

AstraZeneca sells Losec rights as part of refocus strategy

Funds will be diverted to bolster main therapy areas

- PMLiVE

Labour party plans to abolish NHS prescription charges

Comes amid increased focus on drug pricing in the US

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links